Drugmaker Pfizer Inc said on Tuesday it does not yet have data from the late-stage trial of the COVID-19 vaccine it is developing with Germany's BioNTech SE , and provided a timeline that makes its ...
Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...
Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...
Pfizer Inc. (NYSE: PFE, "Pfizer") will present data across its infectious disease portfolio at the upcoming IDWeek 2025 ...
Pfizer Inc. remains attractive with strong fundamentals, cost control, an expanding market, and new drugs. Click here to read ...
Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial –NEW HAVEN, Conn., ...
The Trump administration announced Pfizer has agreed to provide all of its medicines at Most Favored Nation (MFN) pricing in ...
“Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful ...
Sen. Ruben Gallego (D-Ariz.) is raising concerns over the lack of details given about President Trump’s “most favored nation” ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback